C A Q Santos1, D C Brennan2, M A Olsen3. 1. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. Electronic address: csantos@dom.wustl.edu. 2. Division of Renal Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA. 3. Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Abstract
BACKGROUND: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding for cytomegalovirus (CMV) has been used as a proxy for active CMV infection or disease occurring in the inpatient setting in retrospective studies of kidney transplant recipients using large amounts of administrative data. However, the accuracy of inpatient CMV coding has not been determined. METHODS: We identified 393 kidney transplant recipients who were readmitted to Barnes-Jewish Hospital in St. Louis, Missouri from January 1, 2007 to December 31, 2011 to determine the accuracy of the ICD-9-CM diagnosis code for CMV (078.5) in identifying active CMV infection or disease (asymptomatic viremia, CMV syndrome, or tissue-invasive CMV disease) in the inpatient setting, using microbiological, histopathologic, or ophthalmologic evidence for CMV as the gold standard. RESULTS: The sensitivity and positive predictive value of CMV coding in identifying active CMV infection or disease were 0.77 and 0.71, respectively. The specificity and negative predictive value were both 0.98. The sensitivity of CMV coding in identifying CMV syndrome or tissue-invasive CMV disease was 0.93. CONCLUSIONS: CMV coding had good accuracy in identifying active CMV infection or disease among readmitted kidney transplant recipients in our hospital. Further validation studies of CMV coding in other hospitals are needed to obtain more generalizable estimates of the accuracy of CMV coding.
BACKGROUND: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding for cytomegalovirus (CMV) has been used as a proxy for active CMV infection or disease occurring in the inpatient setting in retrospective studies of kidney transplant recipients using large amounts of administrative data. However, the accuracy of inpatient CMV coding has not been determined. METHODS: We identified 393 kidney transplant recipients who were readmitted to Barnes-Jewish Hospital in St. Louis, Missouri from January 1, 2007 to December 31, 2011 to determine the accuracy of the ICD-9-CM diagnosis code for CMV (078.5) in identifying active CMV infection or disease (asymptomatic viremia, CMV syndrome, or tissue-invasive CMV disease) in the inpatient setting, using microbiological, histopathologic, or ophthalmologic evidence for CMV as the gold standard. RESULTS: The sensitivity and positive predictive value of CMV coding in identifying active CMV infection or disease were 0.77 and 0.71, respectively. The specificity and negative predictive value were both 0.98. The sensitivity of CMV coding in identifying CMV syndrome or tissue-invasive CMV disease was 0.93. CONCLUSIONS: CMV coding had good accuracy in identifying active CMV infection or disease among readmitted kidney transplant recipients in our hospital. Further validation studies of CMV coding in other hospitals are needed to obtain more generalizable estimates of the accuracy of CMV coding.
Authors: Carlos Paya; Atul Humar; Ed Dominguez; Kenneth Washburn; Emily Blumberg; Barbara Alexander; Richard Freeman; Nigel Heaton; Mark D Pescovitz Journal: Am J Transplant Date: 2004-04 Impact factor: 8.086
Authors: A Humar; Y Lebranchu; F Vincenti; E A Blumberg; J D Punch; A P Limaye; D Abramowicz; A G Jardine; A T Voulgari; J Ives; I A Hauser; P Peeters Journal: Am J Transplant Date: 2010-03-26 Impact factor: 8.086
Authors: D Blyth; I Lee; K D Sims; L B Gasink; T D Barton; V M Van Deerlin; P Pfeiffenberger; E A Blumberg Journal: Transpl Infect Dis Date: 2012-01-20 Impact factor: 2.228
Authors: A A Boudreault; H Xie; R M Rakita; J D Scott; C L Davis; M Boeckh; A P Limaye Journal: Transpl Infect Dis Date: 2011-03-17 Impact factor: 2.228
Authors: C Cervera; M Fernández-Ruiz; A Valledor; L Linares; A Antón; M Ángeles Marcos; G Sanclemente; I Hoyo; F Cofán; M J Ricart; F Pérez-Villa; M Navasa; T Pumarola; A Moreno Journal: Transpl Infect Dis Date: 2011-04-27 Impact factor: 2.228
Authors: Kevin C Abbott; Iman O Hypolite; Rebecca Viola; Ronald K Poropatich; Paul Hshieh; David Cruess; Clifton A Hawkes; Lawrence Y Agodoa Journal: Ann Epidemiol Date: 2002-08 Impact factor: 3.797
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-05-29 Impact factor: 3.535
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Ocul Immunol Inflamm Date: 2021-03-08 Impact factor: 3.728